^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Excerpt:
We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy....We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLCγ2 in two patients....table 1...
DOI:
https://dx.doi.org/10.1056%2FNEJMoa1400029